HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) and raises the price target from $38 to $40.
August 07, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Protagonist Therapeutics and raises the price target from $38 to $40.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100